WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326874
CAS#: 27470-51-5
Description: Suxibuzone is a analgesic used for joint and muscular pain. It is a prodrug of the non-steroidal anti-inflammatory drug phenylbutazone, and is commonly used in horses.
Hodoodo Cat#: H326874
Name: Suxibuzone
CAS#: 27470-51-5
Chemical Formula: C24H26N2O6
Exact Mass: 438.18
Molecular Weight: 438.480
Elemental Analysis: C, 65.74; H, 5.98; N, 6.39; O, 21.89
Synonym: AE-17; AE17; AE 17; Suxibuzone; Flamilon; Flogos; Solurol.
IUPAC/Chemical Name: 4-((4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid
InChi Key: ONWXNHPOAGOMTG-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)
SMILES Code: O=C(OCC1(CCCC)C(N(C2=CC=CC=C2)N(C3=CC=CC=C3)C1=O)=O)CCC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 438.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Andrews FM, Reinemeyer CR, Longhofer SL. Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses. Vet Ther. 2009 Fall;10(3):113-20. PubMed PMID: 20037965.
2: Sabaté D, Homedes J, Salichs M, Sust M, Monreal L. Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses. Equine Vet J. 2009 Sep;41(7):700-5. PubMed PMID: 19927590.
3: Monreal L, Sabaté D, Segura D, Mayós I, Homedes J. Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses. Res Vet Sci. 2004 Apr;76(2):145-9. PubMed PMID: 14672858.
4: Jaraiz MV, Rodriguez C, San Andres MD, Gonzalez F, San Andres MI. Disposition and tolerance of suxibuzone in horses. Equine Vet J. 1999 Sep;31(5):411-6. PubMed PMID: 10505957.
5: Jaraiz V, Rodriguez C, San Andres MD, Gonzalez F, San Andres MI. Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. J Vet Pharmacol Ther. 1999 Aug;22(4):247-54. PubMed PMID: 10499236.
6: Delbeke FT, Vynckier L, Debackere M. The disposition of suxibuzone in the horse. J Vet Pharmacol Ther. 1993 Sep;16(3):283-90. PubMed PMID: 8230399.
7: Caturla MC, Cusido E. Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds. J Chromatogr. 1992 Oct 2;581(1):101-7. PubMed PMID: 1429991.
8: Yanagi S, Sakamoto M, Takahashi S, Tsutsumi M, Konishi Y, Shibata K, Kamiya T. Promotion of hepatocarcinogenesis by suxibuzone in rats initiated with 3'-methyl-4-dimethylaminoazobenzene. Cancer Lett. 1987 Jul;36(1):11-8. PubMed PMID: 3107799.
9: Mizushima Y, Shiokawa Y, Honma M, Kageyama T. A double-blind comparison of phenylbutazone and suxibuzone, a prodrug of phenylbutazone, in rheumatoid arthritis. Int J Tissue React. 1983;5(1):35-9. PubMed PMID: 6345427.
10: Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, Kageyama T. Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans. J Pharm Sci. 1982 May;71(5):565-72. PubMed PMID: 7097505.
11: Marunaka T, Shibata T, Minami Y, Umeno Y, Shindo T. Simultaneous high-performance liquid chromatographic determination of suxibuzone and its metabolites in plasma and urine. J Pharm Sci. 1980 Nov;69(11):1258-61. PubMed PMID: 7452452.
12: Taira K, Yasuda Y, Shindo T, Mitani N, Akazawa A. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)]. Yakugaku Zasshi. 1980 Mar;100(3):272-9. Japanese. PubMed PMID: 7381687.
13: Shindo T, Yasuda Y, Taira K, Mitani N, Kanda A, Akazawa A. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(sux ibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)]. Yakugaku Zasshi. 1979 Dec;99(12):1186-200. Japanese. PubMed PMID: 120893.
14: Sariols Gómez M. [Clinical efficiency of the anti-inflammatory anesthetic combination suxibuzone-N.A.P.A]. Rev Esp Reum Enferm Osteoartic. 1976;19(3):305-12. Spanish. PubMed PMID: 792973.
15: Erill S, Laporte J. Uricosuric activity of suxibuzone, a new phenylbutazone derivative. Arch Farmacol Toxicol. 1975 Mar;1(1):43-6. PubMed PMID: 1231648.
